Introduction: Limb-girdle muscular dystrophy (LGMD) is the fourth most common muscular dystrophy, with progressive proximal muscle weakness. However, a large number of neuromuscular conditions are similarly presented. Because of this, the use of high-throughput methods such as next-generation sequencing (NGS) is important in the evaluation of LGMD.
Methods: In this report, we applied a custom target capture-based NGS panel covering 31 LGMD-associated genes (MYOT, LMNA, CAV3, DES, DNAJB6, FLNC, CAPN3, DYSF, SGCG, SGCA, SGCB, SGCD, TCAP, TRIM32, FRKP, TTN, POMT1, ANO5, FKTN, POMT2, POMGnT1, DAG1, PLEC, GAA, GMPPB, HNRNPDL, TNPO3, LIMS2, POMK, TRAPPC11, ISPD) in 74 patients suspected of LGMD.
Results: In 25 (33.8%) out of 74 patients analyzed, one or more pathogenic/likely pathogenic variants in 13 different genes were detected. Six of the patients had the variants that were not found in databases and literature; thus, they were interpreted as novel pathogenic variants.
Discussion: The diagnosis rate achieved (33.8%) is consistent with previous literature reports and underlines the efficiency and importance of NGS technology in the molecular genetic evaluation of LGMD.
Keywords: LGMD; NGS; WES; sarcolglycanopathies; variant.
© 2019 John Wiley & Sons Ltd/University College London.
Limb-Girdle Muscular Dystrophy OverviewE Pegoraro et al. PMID 20301582. - ReviewNo definitive treatments for the limb-girdle muscular dystrophies exist. Management should be tailored as much as possible to each individual and each specific LGMD type. …
The Latin American Experience With a Next Generation Sequencing Genetic Panel for Recessive Limb-Girdle Muscular Weakness and Pompe DiseaseJA Bevilacqua et al. Orphanet J Rare Dis 15 (1), 11. PMID 31931849.The results demonstrate the effectiveness of this targeted genetic panel and the importance of including Pompe disease in the differential diagnosis for patients presenti …
Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons LearnedR Ghaoui et al. JAMA Neurol 72 (12), 1424-32. PMID 26436962.With WES, we achieved a diagnostic success rate of 45.0% in our difficult-to-diagnose cohort of patients with LGMD. We expand the clinical phenotypes associated with know …
Genetic Basis of Limb-Girdle Muscular Dystrophies: The 2014 UpdateV Nigro et al. Acta Myol 33 (1), 1-12. PMID 24843229. - ReviewLimb-girdle muscular dystrophies (LGMD) are a highly heterogeneous group of muscle disorders, which first affect the voluntary muscles of the hip and shoulder areas. The …
Autosomal Recessive Limb-Girdle and Miyoshi Muscular Dystrophies in the Netherlands: The Clinical and Molecular Spectrum of 244 PatientsL Ten Dam et al. Clin Genet 96 (2), 126-133. PMID 30919934.In this retrospective study, we conducted a clinico-genetic analysis of patients with autosomal recessive limb-girdle muscular dystrophy (LGMD) and Miyoshi muscular dystr …
- Angelini, C., & Fanin, M. (2017). Limb girdle muscular dystrophies: Clinical-genetical diagnostic update and prospects for therapy. Expert Opinion on Orphan Drugs, 5(10), 769-784.
- Angelini, C., Giaretta, L., & Marozzo, R. (2018). An update on diagnostic options and considerations in limb-girdle dystrophies. Expert Review of Neurotherapeutics, 18(9), 693-703.
- Bushby, K., & Beckmann, J. (1995). The limb-girdle muscular dystrophies-Proposal for a new nomenclature. Neuromuscular Disorders, 5(4), 337-343.
- Carrie, A., Piccolo, F., Leturcq, F., De Toma, C., Azibi, K., Beldjord, C., … Sewry, C. (1997). Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). Journal of Medical Genetics, 34(6), 470-475.
- Chu, M. L., & Moran, E. (2018). The limb-girdle muscular dystrophies: Is treatment on the horizon? Neurotherapeutics, 15(4), 1-14.